Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation?

Kidney International

Volumn 85, Issue 2, 2014, Pages 245-247

  Rostaing, Lionel ^a,b,c   Kamar, Nassim ^a,b,c  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BELATACEPT; BORTEZOMIB; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOGLOBULIN; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STEROID; TACROLIMUS;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; DESENSITIZATION; GRAFT SURVIVAL; HUMAN; IMMUNOADSORPTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MEMORY CELL; PLASMA CELL; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SPLENECTOMY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; SPLENECTOMY;

EID: 84893299002     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.425     Document Type: Note

References (11)

1. Lobashevsky AL, Higgins NG, Rosner KM et al. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation 2013; 96: 182-190
2. Vo A, Choi J, Lukovsky M et al. Interim analysis of a double-blinded placebo controlled trial of IVIG v. IVIG rituximab for desensitization of highly-HLA sensitized (PRA 480%) (HS) deceased donor (DD) candidates. American Transplant Congress: Seattle, WA, 2013 abstr. 153
3. Nozaki T, Ishida H, Shimizu T et al. Excellent long-Term outcome of ABO-incompatible living donor kidney transplantation: A single center experience for over 20 years. American Transplant Congress: Seattle, WA, 2013 abstr. 460
4. Everly MJ, Rebellato LM, Haisch CE et al. Incidence and impact of de novo-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410-417
5. Wiebe C, Gibson IW, Blydt-Hansen TD et al. Evaluation and clinical pathologic correlations of de novo donor-specific HLA antibody post-kidney transplant. Am J Transplant 2012; 12: 1157-1167
6. Liefeldt L, Brakemeier S, Glander P et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192-1198
7. Larsen CP, Bray R, Gebel H et al. Evaluation of donor-specific antibodies in kidney transplant patients treated with belataceptor cyclosporine-based immunosuppression in BENEFIT and BENEFIT-EXT. 15th Congress of the European Society for Organ Transplantation and 22nd Annual Conference of the British Society for Histocompatibility and Immunogenetics; 4-7 September 2011; Glasgow, UK; oral session 29 (abstr. O-244
8. Warren DS, Zachary AA, Sonnenday CJ et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004; 4: 561-568
9. Tyden G, Ekberg H, Tufveson G et al. A randomized, double-blind, placebocontrolled study of single dose rituximab as induction in renal transplantation: A 3-year follow-up. Transplantation 2012; 94: E21-e22
10. Ashimine S, Watarai Y, Yamamoto T et al. Neither pre-Transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Kidney Int 2014; 85: 425-430
11. Kohei N, Hirai T, Omoto K et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469-476